{
    "nct_id": "NCT05912621",
    "official_title": "Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity",
    "inclusion_criteria": "* nondiabetic as defined by fasting plasma glucose < 126 mg/dL while off all glucose lowering medications\n* BMI 27-39.9 kg/m2. Individuals with obesity (BMI 30-39.9 kg/m2) are not required to have an additional risk factor but those who are overweight (27-29.9 kg/m2) must have at least one weight-related factor as follows: hypertension defined as physician-diagnosed and taking antihypertensive medication or SBP> 130 or DBP > 80 mm Hg; dyslipidemia defined as physician diagnosed and taking medication or LDL > 160 mg/dL, TG > 150 mg/dL, HDL < 50 or < 40 mg/dL for women and men, respectively; prediabetes defined as fasting glucose 100-125 mg/dL off all antidiabetic or diabetogenic medications, physician diagnosed obstructive sleep apnea, non-alcoholic fatty liver disease, history of gallstones, and osteoarthritis.\n* Age 18-70\n* Pre and postmenopausal women will be eligible and details of last menstrual period and/or hormone replacement collected for statistical adjustment and formal testing for effect modification.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* prior bariatric surgery or liposuction\n* unstable body weight defined as self-reported weight change >2 kg over the past 6 weeks\n* unstable hypertension (defined as BP >160/100 mm Hg)\n* major organ disease\n* chronic inflammatory conditions\n* pregnancy/lactation\n* active malignancy undergoing treatment\n* use (current or within the past three months) of diabetogenic or weight loss medications, including GLP1 analogs\n* active eating or psychiatric disorder\n* heavy alcohol use (>2 drinks/day for women and > 3 drinks/day for men) will be excluded",
    "miscellaneous_criteria": ""
}